Literature DB >> 25064673

Renal leukocyte chemotactic factor 2 (LECT2) amyloidosis in First Nations people in Northern British Columbia, Canada: a report of 4 cases.

Holly L Hutton1, Mari L DeMarco2, Alex B Magil2, Paul Taylor3.   

Abstract

Leukocyte chemotactic factor 2 (LECT2) amyloidosis is a recently identified type of amyloidosis that may represent an underdiagnosed cause of chronic kidney disease. LECT2 amyloidosis typically is reported as being renal limited and, in the United States, more prevalent in Hispanic patients. We add to the epidemiologic data of this condition by describing 4 First Nations people from Northern British Columbia, Canada, who presented with slowly progressive chronic kidney disease that was found to be due to LECT2 amyloidosis.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  First Nations; Leukocyte chemotactic factor 2 (LECT2); North American indigenous ancestry; amyloid; amyloidosis; chronic kidney disease (CKD); chronic renal failure

Mesh:

Substances:

Year:  2014        PMID: 25064673     DOI: 10.1053/j.ajkd.2014.06.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

Review 1.  Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics.

Authors:  Samih H Nasr; Ahmet Dogan; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

2.  Bystander LECT2 amyloidosis in tumor nephrectomy.

Authors:  A J Gallan; B Bhasin-Chhabra; D Kilari; S Johnson; A D'Souza
Journal:  CEN Case Rep       Date:  2022-08-20

3.  Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians.

Authors:  Christopher P Larsen; Wesam Ismail; Paul J Kurtin; Julie A Vrana; Surendra Dasari; Samih H Nasr
Journal:  Mod Pathol       Date:  2016-02-12       Impact factor: 7.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.